Table 2.
Clinicopathologic characteristics in the residual proliferative cancer burden cohort
| Characteristics | Total or n (%) |
|---|---|
| Patients, n | 85 |
| Age at BC diagnosis, yr | |
| Median (Q1–Q2) | 49.4 (44.5–59.4) |
| Mean | 52.0 |
| Histology | |
| Ductal | 64 (75.3) |
| Lobular | 14 (16.5) |
| Other | 4 (4.7) |
| NA | 3 (3.5) |
| Grade | |
| G1 | 1 (1.2) |
| G2 | 31 (36.5) |
| G3 | 36 (42.3) |
| X | 1 (1.2) |
| NA | 16 (18.8) |
| AJCC stage at diagnosis | |
| II | 35 (41.2) |
| III | 45 (52.9) |
| NA | 5 (5.9) |
| PgR pre‐NACT, % | |
| Median (Q1–Q2) | 65.5 (9–90) |
| Mean | 52.2 |
| <20% | 22 (25.9) |
| ≥20% | 60 (70.6) |
| NA | 3 (3.5) |
| Ki67 pre‐NACT, % | |
| Median (Q1–Q2) | 30 (15.7–40) |
| Mean | 28.37 |
| <20% | 24 (28.2) |
| ≥20% | 52 (61.2) |
| NA | 9 (10.6) |
| NACT | |
| Anthracycline | 4 (4.7) |
| Anthracycline + taxane | 80 (94.1) |
| NA | 1 (1.2) |
| pCR | 10 (11.7) |
| AJCC post‐NACT pathologic stage | |
| 0 | 10 (10.6) |
| I | 14 (17.6) |
| II | 24 (28.2) |
| III | 37 (43.5) |
| Grade post‐NACT a | |
| G1 | 1 (1.3) |
| G2 | 11 (14.7) |
| G3 | 8 (10.7) |
| X | 54 (72.0) |
| NA | 1 (1.3) |
| ER post‐NACT a | |
| ≤10 | 1 (1.3) |
| >10 | 73 (97.4) |
| NA | 1(1.3) |
| Ki67 post‐NACT, median (Q1–Q3), % | 13 (5.0–28.5) |
| Adjuvant systemic therapy a | |
| Chemotherapy | 17 (20.0) |
| Endocrine therapy | 82 (96.5) |
| Recurrence | |
| Total | 31 (36.4) |
| Local | 2 (6.5) |
| Distant | 27 (87) |
| Local + distant | 2 (6.5) |
| Death | 20 (23.5) |
a
Percentage has been computed in relation to the total number of patients with residual disease (n = 95)
Abbreviations: AJCC, American Joint Committee on Cancer; BC, breast cancer; ER, estrogen receptor; NA, not available; NACT, neoadjuvant chemotherapy; pCR, pathologic complete response; PgR, progesterone receptor; Q, quartile.